Three For The Citi: Pfizer, Bristol, GSK Provide R&D, Pricing Briefings
Pfizer’s Mikael Dolsten, Bristol’s Francis Cuss and GSK’s Andrew Witty gave updates on their companies’ progress and direction at the Citi Global Healthcare Conference. Immuno-oncology was a common thread in Dolsten and Cuss’ comments, while Witty talked about GSK’s revised pricing strategies.
You may also be interested in...
The big pharma, which has failed to keep up with rivals in the immuno-oncology field, plans to bring a therapeutic cancer vaccine into the clinic in the next 18 to 24 months, vaccine R&D head Emilio Emini said during a media briefing at the company’s headquarters Sept. 10.
Pfizer’s emphasis on oncology has yielded three new drug approvals in the last 20 months and another two promising drugs on the horizon. It is a notable achievement, but investors may be wondering when the results are going to be felt on the top line.
U.K. pharma giant’s growth will come from a diversified, innovative portfolio of medicines, emerging markets, vaccines, and “bolt-ons.”